Articles from Vividion Therapeutics, Inc.

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a manuscript in Science describing the discovery and preclinical characterization of small molecules that inhibit RAS-dependent PI3Kα oncogenic signaling by specifically blocking the interaction between RAS and PI3Kα, without disrupting homeostatic signaling.

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the appointment of Sam Whiting, M.D., Ph.D., as Chief Medical Officer. Dr. Whiting is an accomplished medical oncologist who brings to Vividion more than two decades of experience spanning patient care, early drug discovery, and late-stage global clinical development. Vividion utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020. Vividon utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers. Vividion is a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, utilizing innovative discovery technologies to unlock targets with strong disease-link, yet traditionally undruggable and develop small molecule precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the promotion of Jean Bemis to Chief Operating Officer.

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.

Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced the appointment of Frank Poschen, a pioneer in organizational change and dynamic talent leader, to its Board of Directors and as Chair of the Compensation Committee. Mr. Poschen, Senior Vice President of Global HR Pharmaceuticals at Bayer, will replace Christoph Bertram, Ph.D., who ended his active employment with Bayer and stepped down from his roles as Director on Vividion’s Board of Directors, Chair of the Compensation Committee, and Senior Vice President of Global HR Pharmaceuticals at Bayer, effective September 23, 2024

Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature. The publication, “Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase,” by Kristen Baltgalvis et al, published jointly with our partner Roche, speaks to the chemical proteomic-enabled discovery of a clinical-stage, covalent allosteric inhibitor of Werner helicase (WRN), VVD-133214 (RO7589831), and further confirms Vividion’s approach to discovering and developing novel therapeutics.

Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors. Vividion is a biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, utilizing innovative discovery technologies with the potential to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The start of the trial represents another major milestone for Vividion’s innovative chemoproteomics platform.

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies and advanced science to find new solutions for devastating cancers and immune disorders, has been recognized as a Top Workplaces 2023 award winner by the San Diego Union-Tribune for the second year in a row. The annual competition involves San Diego area companies of all sizes and industries. Awards are based on rankings from anonymous company-wide employee surveys that measure culture drivers critical to the success of any organization such as: leadership, connection, alignment, coaching, engagement and performance. In addition, Vividion won the “Direction” award where our employees believe “we are going in the right direction.”

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Dr. Shawn Rose, M.D. Ph.D., has joined the company as Chief Development Officer (CDO), Immunology, reporting to our Chief Executive Officer, Aleksandra Rizo.

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer.

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies and advanced science to find new solutions for devastating cancers and immune disorders, has been recognized as a Top Workplaces 2022 award winner by the San Diego Union-Tribune. The annual competition involves San Diego area companies of all sizes and industries. Awards are based on rankings from anonymous company-wide employee surveys that measure culture drivers critical to the success of any organization such as: engagement, strategic direction, inclusion, transparency, cooperation, and support for personal growth.

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the formation of a scientific advisory board (SAB) comprised of industry leaders in oncology, immunology, drug development and chemical biology. The SAB will work cohesively with the Vividion team to advance the company’s programs based on its proprietary chemoproteomic platform.

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that it has earned its first milestone payment related to its exclusive worldwide collaboration, option and license agreement with Roche. The payment follows Vividion’s completion of a preclinical data package for a program addressing a well-known, but difficult to drug target, for the potential treatment of oncology indications.

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.